A quiet revolution is underway in Indian oncology. Chinese-origin cancer drugs, brought to India through a growing number of pharma partnerships, are dramatically cutting the cost of immunotherapy — making treatment accessible to patients who previously had no options. Doctors are prescribing them, patients are responding well, and Indian companies — from Glenmark to Dr Reddy’s to Intas — are signing billion-dollar deals to expand access further. Western immunotherapy can cost up to five lakh rupees per session. Chinese-origin alternatives are bringing that down to fifty thousand. This episode explores how the India-China pharma axis is reshaping who gets treated, and how.